Quest Diagnostics reported Q2 2026 revenue of $3.04 billion, up 10.2%, with adjusted earnings per share of $3.12, topping analyst estimates. Diagnostic Information Services grew about 10.3% to $2.98 billion as requisition volumes rose 13.1%, reflecting strong demand across physician, hospital and consumer channels. The company raised its full-year outlook, now guiding 2026 revenue to $11.95–$12.05 billion and adjusted EPS to $11.05–$11.25, above prior targets and consensus. Shares moved higher in premarket trading on the results, signaling investor optimism about the raised outlook. Industry coverage noted that demand remained robust and that Quest’s long-term growth trajectory remains a key focus, alongside comparisons to peers like Labcorp. Some reports also highlighted insider trading activity among Quest executives, though this did not alter the core demand and earnings narrative for the quarter.